Business Wire

HCL Technologies Selected by Cricket Australia as Digital Technology Partner

Share

HCL Technologies (HCL) and Cricket Australia (CA) have today announced a multi-year partnership, with HCL being chosen as the Digital Technology Partner of CA.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190619005284/en/

HCL Technologies and Cricket Australia exchanging mementos to announce digital partnership. Standing ...

HCL Technologies and Cricket Australia exchanging mementos to announce digital partnership. Standing left to right: Brad Hodge, former Australian international cricketer, & current cricket coach; Arthur Fillip, Executive Vice President - Sales Transformation & Marketing; Kevin Roberts, CEO, Cricket Australia; Swapan Johri, Corporate Vice President & Head - Asia/Pacific & Middle East Business; Belinda Clarke, Executive General Manager, Community Cricket & former captain of the Australian Women's Cricket Team (Photo: Business Wire)

HCL, a leading global technology company, will help the Australian cricket’s governing body provide an elevated and immersive digital experience to cricket fans, players, partners, employees, and volunteers across the country and around the world, through CA’s digital offerings.

HCL will implement its Scale Digital methodology to enable Cricket Australia to unite and inspire their cricket community through advanced digital platforms.

Cricket Australia selected HCL Technologies following an extensive search for a trusted digital partner that has proven credentials in enabling digital transformation journey for leading global businesses, enhancing ecosystem orchestration, improving business agility and delivering unique experiences to all users and stakeholders.

Cricket Australia CEO Kevin Roberts said:

“Cricket is rapidly evolving here and overseas, and part of that evolution involves advancements in technology and the digital landscape.

“Cricket Australia is connecting with fans and participants through our digital platforms every minute of the day, through the stories and live match data on cricket.com.au right through to participants and community volunteers using our MyCricket platform.

“The usage of these platforms continues to grow significantly, so partnering with a leading global technology provider to harness this growth and help us take advantage of our leading position is a natural next step.

“HCL, as our Official Digital Technology Partner, will help take our digital offerings to the next level and allow us to better connect with and inspire communities through cricket,” Roberts said.

HCL will engineer a digital core ecosystem for Cricket Australia through a composable platform that will be modular, auto-scalable, data driven and experience-centric, integrating multiple industry standard products and services to enhance the experience for fans and participants.

As the world’s leading provider of digital transformation for major professional sports organizations, HCL will manage and elevate CA’s suite of digital products that lead the way in Australia for digital consumption, including properties such as the Cricket Australia Live App, cricket.com.au, bigbash.com.au and community cricket applications such as MyCricket and community.cricket.com.au.

“We are thrilled to partner with Cricket Australia and believe that this partnership will serve as a blueprint for organisations worldwide who are exploring technology platforms that can scale existing value chains into ecosystem-centric business models, resulting in inspiring and exceptional experiences,” said Michael Horton, HCL Executive Vice President & Country Manager, Australia & New Zealand. “The vision of this partnership is to continue igniting passion for the game and to grow lifelong fans for the wonderful sport of cricket. We look forward to providing the Australian cricket community with leading-edge digital technologies that support real-time, engaging, personalized and unified experiences.

“HCL understands the importance of retaining and engaging fans in today’s digital world,” said Michael Horton, HCL Technologies. “We look forward to deploying our skills and experience to increase fan delight, high performance and community inspiration for the love of cricket.”

The cricket-following community is substantial in Australia, with more than 2 million fans attending cricket matches during the 2018/19 season. Around the world, the sport of cricket has a fan base of over 2.5 billion passionate followers.

Digitally, CA has an online audience exceeding 20 million globally per year and has established and maintained its position as the No.1 sports destination in Australia throughout the summer, achieving a record unique Australian audience of 2.87 million in January 2019 alone.

The HCL partnership is designed to further enhance CA’s digital presence and impact.

For more information, please visit www.hcltech.com/cricket-australia.

About Cricket Australia

Cricket Australia (CA) is the national governing body for the game in Australia.

Australian cricket is administered by one national body (CA) and its members, the six state and two territory associations. Cricket Australia's vision is for cricket to be Australia’s favourite sport, and a sport for all Australians. Its purpose is to unite and inspire communities through cricket.

Click here to read the Australian Cricket Strategy (2017-2022): https://www.cricketaustralia.com.au/about/our-strategy

Contact information

Cricket Australia
Josh Marton, CA Communications
(+61) 410 651 251

HCL Technologies
Arpit Gupta, ANZ
arpitgupta@hcl.com

Devneeta Pahuja, APAC & India
devneeta.p@hcl.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kite Announces Long-term Data From ZUMA-1 Showing Approximately Half of Refractory Large B-cell Lymphoma Patients Were Alive Three Years After Yescarta Treatment7.12.2019 19:00:00 CETPress release

Kite, a Gilead Company (Nasdaq: GILD), today announced new data from the ZUMA-1 trial of Yescarta® (axicabtagene ciloleucel) in adult patients with refractory large B-cell lymphoma. These results included updated overall survival data from the pivotal phase 2 study after three years following a single infusion of Yescarta, as well as an analysis from a separate safety management cohort of patients receiving early steroid intervention for cytokine release syndrome (CRS) and neurologic events. The data were presented today at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition, in Orlando from December 7–10, 2019. With a minimum follow-up of three years after a single infusion of Yescarta (median follow-up of 39.1 months), approximately half (n=47/101; 47 percent) of patients with refractory large B-cell lymphoma in ZUMA-1 pivotal phase 2 cohorts were alive, and the median overall survival (OS) was 25.8 months. These updated three-year survival data were presented a

Janssen Presents Initial Results for BCMA CAR-T Therapy JNJ-4528 Showing Early, Deep and High Responses in the Treatment of Relapsed or Refractory Multiple Myeloma7.12.2019 15:20:00 CETPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today initial results from the Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of JNJ-68284528 (JNJ-4528), an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy being evaluated in the treatment of patients with relapsed or refractory multiple myeloma. The study enrolled patients who had received at least three prior lines of therapy or were double refractory to a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD); had received a PI, IMiD and an anti-CD38 antibody. The CARTITUDE-1 study results, premiered at the American Society of Hematology (ASH) Annual Meeting, were featured as an oral presentation and highlighted in the official ASH press programme (Abstract #577).1 Results from the Phase 1b portion of the CARTITUDE-1 study showed early and deep responses among patients (n=29) with a median of five prior multiple myeloma

Imbruvica®▼(ibrutinib) Combination Therapy Data From Two Studies and Long-Term Integrated Analysis Presented at ASH 2019 Show Efficacy and Safety in First-Line Treatment of Chronic Lymphocytic Leukaemia7.12.2019 15:18:00 CETPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced combination data from two studies and a long-term integrated analysis evaluating the use of Imbruvica® (ibrutinib) for the treatment of previously untreated patients with CLL. Results from a 48-month follow-up analysis of the Phase 3 E1912 clinical study reported a statistically significant difference in PFS and OS for ibrutinib plus rituximab compared to a standard chemoimmunotherapy regimen of FCR.1 Further, the latest integrated analysis from the Phase 3 RESONATETM (PCYC-1112) and RESONATETM-2 (PCYC-1115/1116) studies investigating the use of single-agent ibrutinib in CLL, reported at up to six years of follow-up, PFS, OS and response rates improved when ibrutinib was used in earlier lines of therapy.2 During this extended follow-up, ibrutinib was tolerated across all lines of therapy with 19 percent of patients discontinuing due to adverse events.2 In addition, results presented from the Phase 2 CAPTIVATE stu

Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis7.12.2019 14:30:00 CETPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that results of the TOURMALINE-AL1 trial will be presented during an oral session at the 61st American Society of Hematology (ASH) annual meeting on Saturday, December 7, 2019 in Orlando, Florida. TOURMALINE-AL1 is a Phase 3, randomized clinical trial evaluating the effect of NINLAROTM (ixazomib) in combination with dexamethasone in patients with relapsed or refractory systemic light-chain (AL) amyloidosis. The TOURMALINE-AL1 trial did not meet the first of the two primary endpoints of significant improvement in overall hematologic response, as reported in June 2019. Hematologic responses were seen in 53% versus 51% of patients receiving NINLARO plus dexamethasone versus physician’s choice (odds ratio 1.10 [95% CI 0.60-2.01], p=0.762) as assessed by an Adjudication Committee (AC). The second primary endpoint of two-year vital organ deterioration or death was not mature at the time of analysis. Other endpoints stu

Schlumberger Announces Fourth-Quarter and Full-Year 2019 Results Conference Call6.12.2019 18:07:00 CETPress release

Schlumberger Limited (NYSE:SLB) will hold a conference call on January 17, 2020 to discuss the results for the fourth quarter and full year ending December 31, 2019. The conference call is scheduled to begin at 8:30 am US Eastern time and a press release regarding the results will be issued at 7:00 am US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (844) 721-7241 within North America or +1 (409) 207-6955 outside of North America approximately 10 minutes prior to the start of the call and the access code is 4013483. A webcast of the conference call will be broadcast simultaneously at www.slb.com/irwebcast on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until February 17, 2020, and can be accessed by dialing +1 (866) 207-1041 within North Amer

BUFF STUDIO Globally Launches My Coloring, a Mobile 3D Pixel Art Coloring Book Game6.12.2019 13:00:00 CETPress release

BUFF STUDIO announced on December 5 that it launched My Coloring, a mobile 3D pixel art coloring book game, in 155 countries simultaneously. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191206005162/en/ BUFF STUDIO launched My Coloring, a mobile 3D pixel art coloring book game, in 155 countries simultaneously. My Coloring is a game that materializes a 3D pixel art coloring book on mobile devices. You can blow your stress away as you paint spaces in the order of numbers on the screen while reading calming messages. Relaxing background music you will listen during gameplay and its fairytale-like design will give you pleasure and happiness. You can download it for free on Google Play and the Apple App Store. (Graphic: Business Wire) Its Android and iOS versions were released at the same time so the users can download it for free on Google Play and the Apple App Store. My Coloring is a game that materializes a 3D pixel art col